Quotables
"That’s an amazing invention, but who would ever want to use one of them?"
President Rutherford B. Hayes ; Said in 1876, after Alexander Graham Bell demonstrated the telephone to him at the White House
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173653 | Pyridiazinone derivatives for the treatment of tumours Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors. ... | 05/08/2012 |
| 8143252 | Tetrahalogenated compounds useful as inhibitors of angiogenesis Methods for inhibiting a neoplasm in a subject and methods of inhibiting undesired angiogenesis that include administering to a subject a therapeutically effective amount of at least one novel tetrahalogenated compound, or a pharmaceutically acceptable salt thereof.... | 03/27/2012 |
| 8138187 | Substituted heteroaryl derivatives The invention relates to substituted heteroaryl derivatives, to methods for the production thereof, to medicaments containing said compounds and to the use of substituted heteroaryl derivatives for producing medicaments. ... | 03/20/2012 |
| 8110575 | Compounds The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as in the description, the tautomers, the isomers, the... | 02/07/2012 |
| 8101610 | Bisamide inhibitors of hedgehog signaling The invention provides inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein ring A, ring B, R1, R2,... | 01/24/2012 |
| 8101611 | Substituted pyridazines inhibitors of MEK Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the spe... | 01/24/2012 |
| 8097625 | Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor ... | 01/17/2012 |
| 8097626 | IL-8 receptor antagonists This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (Il-8). ... | 01/17/2012 |
| 8084452 | Substituted enaminocarbonyl compounds used as insecticides The present application relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects. ... | 12/27/2011 |
| 8080549 | Endothelin receptor antagonists This invention relates to novel endothelin receptor antagonists, derivatives, acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases an... | 12/20/2011 |
| 8071596 | Endothelin receptor antagonists This invention relates to novel endothelin receptor antagonists, derivatives, acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions... | 12/06/2011 |
| 8048884 | Substituted piperazinyl pyrazines and pyridines as 5-HTreceptor antagonists The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine: where A is —C(H)═ or —N═; m is 0, 1 or 2; R1 is optional... | 11/01/2011 |
| 8048883 | Polymorphic form of imatinib mesylate and a process for its preparation This invention discloses a novel stable crystal form of imatinib mesylate, designated by us as α2 Form, which is stable at room temperature and even at higher temperatures up to 120° C. and accelerated stress conditions and, freely soluble in water. Thi... | 11/01/2011 |
| 8030304 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and m... | 10/04/2011 |
| 8026238 | Topical antifungal composition A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component c... | 09/27/2011 |
| 8026239 | Cell differentiation inducer A method of treating a malignant tumor selected from the group consisting of leukemia, colorectal cancer, ovarian cancer, oral cancer, lung carcinoma, breast carcinoma, prostate carcinoma, and melanoma by administering to a patient in need thereof an effective amoun... | 09/27/2011 |
| 8017609 | Method for the prevention of thromboembolic disorders A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need... | 09/13/2011 |
| 7977332 | Insecticidal N-(heteroarylalkyl)alkanediamine derivatives Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, Ra, Rb, Rc, Rd, b, c, Re | 07/12/2011 |
| 7923446 | Biaryl sulfonamides and methods for using same The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors. ... | 04/12/2011 |
| 7923447 | Parenteral solutions containing metolazone Disclosed herein are parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamide in N,N-dimethylactamide, polyethylene glycol and D5W useful in the treatment of hypertension, heart failure and renal disease leading to edemat... | 04/12/2011 |
| 7910586 | Compositions and methods for prevention and treatment of amyloid-β peptide-related disorders The present invention provides methods and compositions for modulating levels of amyloid-β peptide (Aβ) exhibited by cells or tissues. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate Aβ levels. The inve... | 03/22/2011 |
| 7893065 | Heterocyclic inhibitors of MEK and methods of use thereof Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, and W are as defined in the specificati... | 02/22/2011 |
| 7872008 | Method for treating insulin resistance, abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids with a cortisol inhibitor The invention concerns the use of ketoconazole and derivatives having a corresponding biological activity, and combinations thereof, in the treatment of abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids. ... | 01/18/2011 |
| 7820663 | Substituted enaminones, their derivatives and uses thereof The present invention is related substituted enaminones represented by a compound of Formula I that are novel allosteric modulators of α7 nAChRs. The invention also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on ... | 10/26/2010 |
| 7807674 | Thyroid hormone analogs Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositi... | 10/05/2010 |
| 7795258 | Pyridazine compound and use thereof A pyridazine compound represented by formula (1): wherein R1 and R2 are same or different and represent a C1-C4 alkyl group; R3 represents a halogen atom, a nitro group, a cyano group, a C1-... | 09/14/2010 |
| 7732445 | Myosin light chain kinase inhibitor compounds, compostions and related methods of use Pyridazinyl compounds, compositions and related methods of use. ... | 06/08/2010 |
| 7678794 | Potentiators of glutamate receptors The present invention provides a compound of formula (I): pharmaceutical compositions thereof, and methods of using the same, processes for preparing the same, and intermediates thereof. ... | 03/16/2010 |
| 7659272 | CCR9 inhibitors and methods of use thereof The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compound... | 02/09/2010 |
| 7638516 | Agent for therapeutic treatment of optic nerve diseases and the like The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in trans... | 12/29/2009 |
| 7638515 | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents The invention relates to tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents. ... | 12/29/2009 |
| 7625898 | Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof Improved posaconazole-based compositions and methods of treating and preventing fungal infections, cancer or metastatic diseases are disclosed. In preferred aspects, the conjugates are PEG-posaconazole conjugates in which the PEG has a molecular weight of about 20,0... | 12/01/2009 |
| 7618969 | Compounds which potentiate glutamate receptor and uses thereof in medicine Compounds of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, are disclosed: wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-... | 11/17/2009 |
| 7608621 | N-substituted glycine derivatives: hydroxylase inhibitors The invention described herein relates to certain pyridazinedione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the in... | 10/27/2009 |
| 7601715 | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein A process is provided for preparing triazole substituted azaindoleoxoacetic piperazine derivative. Novel intermediates produced in the above process, and novel N-1 and amorphous forms of a 1,2,3-triazole substituted azaindoloxoacetic piperazine derivatives and proce... | 10/13/2009 |
| 7598247 | Immunomodulating heterocyclic compounds Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R1 and R3 independently represent H; F; Cl; Br; —NO2; —CN; C1-C6 alk... | 10/06/2009 |
| 7595317 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases The present application describes novel barbituric acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R1, R2, R3, R4, R | 09/29/2009 |
| 7595316 | Heteroaryloxy nitrogenous saturated heterocyclic derivative Compound of the formula: (I) [wherein each of X1, X2 and X3 independently represents N or CH, W represents the formula (II):(II) or the formula (III):(III) and Y represents a group of the formula (IV):(IV)], or a pharmacologically ac... | 09/29/2009 |
| 7579350 | Scaffolds for α-helix mimicry Functionalized pyridazine derivatives having a low molecular weight and pharmaceutical compositions thereof are useful as alpha-helix mimetics and for treating conditions and/or disorders mediated by alpha-helix-binding receptors and proteins. ... | 08/25/2009 |
| 7553835 | Topical antifungal composition The subject matter relates to a topical, foamable composition including at least one antifungal agent, said composition characterised in that said at least one antifungal agent is able to penetrate the upper layers of skin and is retained in or on an area to be trea... | 06/30/2009 |
